Endocrine Abstracts

Introduction: The majority of patients with radioiodine-refractory thyroid carcinoma (RAIR-TC) have an indolent disease and require active surveillance (AS) only, while those with progression of the disease (PD) may benefit from local treatment (LT) or systemic therapy with tyrosine-kinase inhibitors (TKI). In the literature, no data about the real impact of LTs in avoiding/delaying systemic treatment in RAIR-TC patients are present.Objective: This study...

Introduction: Ethanol ablation (EA) of “persistent or recurrent” neck nodal metastases (NNM) in adult papillary thyroid carcinoma (APTC) patients was first introduced in 1993 to clinical endocrine oncologic practice (JCEM 2011;96: 2717). At Mayo Clinic we have been impressed by the efficacy of EA in controlling postoperative NNM in stage I APTC patients. We now describe the long-term outcome results of EA in controlling recurrent NNM in 41 patients consecutively mana...

Background: Tyrosine kinase inhibitors (TKIs) are modern antineoplastic molecules widely used in the medical treatment of many cancers including iodine refractory differentiated thyroid carcer (DTC) and advanced medullary thyroid cancer (MTC). In patients with thyroid gland, TKIs frequently cause a destructive and/or autoimmune thyroiditis with consequent hypothyroidism. However, authors have reported unexpected TSH increase or hypothyroidism even in patients with total thyroi...

Introduction and objectives: Lenvatinib is the first line treatment for advanced radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC). Poorly differentiated thyroid carcinoma (PDTC) outcomes with Lenvatinib have only been subjected to sub analysis in one PHASE III study (SELECT), which might limit its real-world use in PDTC. We intend to compare the effectiveness of Lenvatinib in metastatic RAIR DTC and PDTC patients.Methods: Retrospectiv...

Objectives: AJCC/TNM staging system provides an estimate of mortality risk in differentiated thyroid cancer (DTC) patients and recent evidence showed that ATA risk stratification may improve the definition of this risk. We speculated that the integration of the response to the initial therapy (RIT) could better define the mortality risk.Methods: We retrospectively evaluated 891 consecutive DTC patients followed at the Section of Endocrinology, University...

Introduction: The combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) was approved by the Food and Drug Administration in USA as first line treatment for BRAF-positive anaplastic thyroid cancer. Moreover, it was also available as second line treatment in BRAF-positive advanced thyroid cancers, previously treated with other systemic treatments.Purpose: We evaluated the efficacy and safety of the combination therapy with dabrafenib an...

Background: Several adverse events are recorded during treatment with tyrosine-kinase inhibitors (TKIs). Hypocalcemia was reported during phase III clinical trials with both Lenvatinib and Vandetanib, but scanty data are available in a real-life setting. Aim of our study was to evaluate hypocalcemia occurrence and its characteristics in a cohort of patients treated with these drugs for advanced thyroid cancer. Moreover, in patients treated with Lenvatinib, we examined a possib...

Therapeutic strategy for the management of radioiodine-refractory differentiated thyroid cancer (rrDTC) and advanced medullary thyroid cancer (MTC) had changed with the introduction of the multityrosine-kinase-inhibitors (MKI) sorafenib&lenvatinib and vandetanib&cabozantinib respectively. Only recently, the market approval of pralsetinib (FDA) and selpercatinib (FDA and EMA) as first highly selective RET(rearranged during transfection)- inhibitors have expande...

Background: Anaplastic thyroid carcinoma (ATC) is associated with the highest mortality risk of any thyroid-arising tumor; however, there is currently no effective therapy for ATC, and multimodal therapy is associated with a relatively high mortality risk. Here, we investigated the effects of neoadjuvant chemoradiotherapy on patients with ATC treated with paclitaxel and intensity-modulated radiation therapy (IMRT).Methods: The medical records of 157 pati...